Riitta Lahesmaa
MD, PhD, Professor
rilahes@utu.fi +358 29 450 2415 +358 40 718 4813 Tykistökatu 6 Turku ORCID identifier: https://orcid.org/0000-0002-4782-9567 |
Immunology
Immune regulation
Type 1 diabetes
inflammation
autoimmune diseases
biomarkers
InFLAMES Flagship, Immunology
I have been the Director of Turku Bioscience Centre, Turku, Finland (https://bioscience.fi/) since 1998. I am also Professor of Systems Immunology at Medical Faculty of University of Turku, institute of Biomedicine.
I got M.D. and Ph.D. in immunology from the University of Turku. I was a postdoctoral fellow at Stanford University Medical Center and a Principal Scientist at Roche Bioscience in Palo Alto, California. I have been a visiting professor at Harvard Medical School, Stanford University and UCSF. I founded and directed Turku Centre for Systems Biology 2000-2015 and was vice-director of The Academy of Finland Centre of Excellence in Systems Immunology and Physiology. I was the Academy Professor of the Academy of Finland in 2016-2020.
I am a member of the board of Scandinavian Society of Immunology. I have published > 250 original papers and reviews and have several issued patents and patent applications. I am an elected member of the Finnish Academy of Science and Letters since 2012.
Web-site: https://bioscience.fi/research/molecular-systems-immunology/profile
My research in molecular systems immunology aims at understanding molecular mechanisms of regulation of human immune response and pathogenesis of type 1 diabetes and other human immune mediated diseases. T cells orchestrate our immune system and a proper balance of T cells is crucial for immune defense in healthy individuals. In autoimmune diseases, out-of-control T cells drive pathologic inflammatory responses with devastating consequences for patients. Our studies have resulted in the identification of novel molecular mechanisms and new regulators of T cell functions. Our projects in progress aim at understanding the molecular basis of immune regulation to enable its modulation. Moreover, we aim at understanding the early immune response in children who develop Type 1 Diabetes to identify new biomarkers to improve predicting, monitoring, and early diagnosis of beginning of the disease process. This is of fundamental importance to be able to select the right patients for potential interventions as soon as the disease process kicks in.
Web-site: https://bioscience.fi/research/molecular-systems-immunology/profile/
My main contribution to
teaching is to train PhD students and postdoctoral fellows. Over the years I
have supervised 35 postdoctoral researchers of whom 29 completed, six in
progress and 34 PhD students of whom 28 completed, six in progress.
- Immunologinen toleranssi ja FOXP3: fysiologian tai lääketieteen Nobelin palkinto 2025 (2026)
- Duodecim
(D1 Article in a professional journal) - Microbiome-derived bile acid signatures in early life and their association with islet autoimmunity (2026)
- Nature Communications
(A1 Refereed original research article in a scientific journal) - Staphylococcus aureus Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma (2026)
- Allergy
(A1 Refereed original research article in a scientific journal) - Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease (2026)
- BMC Medicine
(A1 Refereed original research article in a scientific journal) - Transcriptomics of type 1 diabetes progression: a validation study in newly diagnosed patients (2026)
- EBioMedicine
(A1 Refereed original research article in a scientific journal) - Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes (2025)
- Science Advances
(A1 Refereed original research article in a scientific journal) - LINC01871 is exclusively expressed in T and NK cells and is highly induced upon CD4+ T cell activation (2025)
- iScience
(A1 Refereed original research article in a scientific journal) - Single-cell RNA-seq analysis of longitudinal CD4+ T cell samples reveals cell-type-specific changes during early stages of type 1 diabetes (2025)
- Genome Medicine
(A1 Refereed original research article in a scientific journal) - Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes affirms markers of disease (2025)
- Diabetologia
(A1 Refereed original research article in a scientific journal) - A proximal enhancer regulates RORA expression during early human Th17 cell differentiation (2024)
- Clinical Immunology
(A1 Refereed original research article in a scientific journal)



